Bupropion/dextromethorphan

Bupropion/dextromethorphan (developmental code name AXS-05) is a combination drug of bupropion (Wellbutrin), a norepinephrine-dopamine reuptake inhibitor (NDRI) and nicotinic acetylcholine receptor (nAChR) antagonist, and dextromethorphan (DXM), a sigma-1 receptor agonist, NMDA receptor antagonist, and serotonin-norepinephrine reuptake inhibitor (SNRI), which is under development by Axsome Therapeutics for the treatment of treatment-resistant major depressive disorder (MDD) and agitation in Alzheimer's disease.[1][2][3] Via inhibition of CYP2D6, similarly to quinidine, bupropion slows the metabolism of DXM and thereby increases its levels. As of 2017, the combination is in phase III clinical trials for the aforementioned indications.[1]

Bupropion/dextromethorphan
Bupropion
Dextromethorphan
Combination of
BupropionNorepinephrine reuptake inhibitor and nicotinic acetylcholine receptor antagonist
DextromethorphanSigma-1 receptor agonist, NMDA receptor antagonist, serotonin-norepinephrine reuptake inhibitor
Clinical data
Routes of
administration		Oral
Legal status
Legal status

See also

References
  1. "Bupropion/dextromethorphan - Axsome Therapeutics". Adis Insight. Springer Nature Switzerland AG.
  2. Wilkinson ST, Sanacora G (February 2019). "A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems". Drug Discovery Today. 24 (2): 606–615. doi:10.1016/j.drudis.2018.11.007. PMC 6397075. PMID 30447328.
  3. "Axsome depression drug meets late-stage study goal, shares soar 56%". Reuters. 16 December 2019 – via www.reuters.com.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.